Why Quetiapine (Seroquel) Is Overprescribed for Insomnia

Is quetiapine actually approved as a sleep medication?

No. Quetiapine (brand name Seroquel) is an atypical antipsychotic that the Food and Drug Administration approved for schizophrenia, bipolar disorder, and as an add-on treatment for major depression — not for insomnia. Prescribing it for sleep is off-label use: legal, sometimes reasonable, but outside anything the drug's approval or its safety studies were designed to prove.

Off-label prescribing is common across psychiatry and sleep medicine, so the label gap alone doesn't settle the question. What matters is whether the evidence behind that particular off-label use holds up on its own terms — and for quetiapine, it looks thin next to other sedating drugs that are also reached for off-label when someone can't sleep.

How does the evidence for quetiapine compare with better-studied off-label options?

It compares poorly. The clinical guideline that evaluates individual off-label sleep medications by name — melatonin, trazodone, diphenhydramine, tryptophan, valerian — issues only weak recommendations for nearly all of them, citing insufficient evidence 1Ref 1Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017).Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.AASM's drug-by-drug guideline gives only weak recommendations against melatonin, trazodone, diphenhydramine, tryptophan, and valerian for insomnia, citing insufficient evidence — the weak-evidence framing for individually evaluated off-label hypnotics; quetiapine is not among the agents this guideline evaluates.. Quetiapine doesn't appear on that evaluated list at all — it hasn't been studied for insomnia with the rigor even the guideline's weakest-recommended options received.

Trazodone is the clearest comparison, because it's the most commonly used off-label sleep aid and it has its own dedicated systematic review. That review found only modest efficacy for sleep continuity, built on a limited base of high-quality trials 2Ref 2Jaffer KY, Chang T, Vanle B, et al. (2017).Trazodone for Insomnia: A Systematic Review.Systematic review finding modest efficacy and a limited base of high-quality evidence for low-dose trazodone used off-label for insomnia.. If the field's most-studied off-label option still rests on modest, low-quality evidence, a drug with no dedicated insomnia trials behind it at all is a considerably bigger leap.

What does quetiapine's risk profile add that a sleep-specific drug wouldn't?

It falls outside a safety framework built for actual sleep drugs. In 2019 the FDA added a boxed warning to the prescription medicines actually labeled for insomnia — zolpidem, eszopiclone, and zaleplon — after reports of serious injury and death from sleepwalking, sleep-driving, and other complex behaviors performed while not fully awake 3Ref 3US Food and Drug Administration (2019).Certain Prescription Insomnia Medicines: New Boxed Warning — Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake.FDA's 2019 boxed warning on complex sleep behaviors applies specifically to the insomnia-labeled prescription drugs zolpidem, eszopiclone, and zaleplon.. Quetiapine was never part of that review; it was never labeled for insomnia to begin with.

That gap cuts both ways. It means quetiapine hasn't accumulated the same documented signal for those specific sleep behaviors, but it also means nobody has looked as hard, in a study built for that purpose. Prescribing a sedating antipsychotic for sleep means extrapolating from its psychiatric safety data rather than relying on insomnia-specific trials — a reasonable last resort in some situations, and a poor first move in most.

The absence of an insomnia-specific safety review is not the same thing as evidence of safety. It simply means the specific question this article is asking — is quetiapine a good sleep aid — has not been the question any large trial was designed to answer. That distinction matters more than it might seem, because it's easy to mistake an unstudied risk for a small one.

What does the evidence-based alternative to a pill look like?

The strongest-evidence path runs through cognitive behavioral therapy for insomnia (CBT-I), not through any medication. The American Academy of Sleep Medicine gives multicomponent CBT-I its strongest possible recommendation for chronic insomnia disorder, and explicitly advises against sleep hygiene advice alone as a standalone treatment 4Ref 4Edinger JD, Arnedt JT, Bertisch SM, et al. (2021).Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline.AASM's strong recommendation for multicomponent CBT-I in chronic insomnia disorder, and its recommendation against sleep hygiene alone as a standalone treatment.. The joint Department of Veterans Affairs and Department of Defense clinical practice guideline reaches the same conclusion: CBT-I first, medication second 5Ref 5Mysliwiec V, Martin JL, Ulmer CS, et al. (2020).The Management of Chronic Insomnia Disorder and Obstructive Sleep Apnea: Synopsis of the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines.VA/DoD joint clinical practice guideline recommending CBT-I as first-line treatment for chronic insomnia..

Limited access, not a shortage of evidence, is the real bottleneck. A nurse-delivered version of one CBT-I component, sleep restriction therapy, improved insomnia severity and proved more cost-effective than simple sleep-hygiene advice in a large pragmatic trial run through ordinary primary-care clinics — evidence that the approach can scale well past a specialist's waitlist 6Ref 6Kyle SD, Siriwardena AN, Espie CA, et al. (2023).Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial.Pragmatic primary-care RCT (n=642) showing nurse-delivered sleep restriction therapy improved insomnia severity and was cost-effective versus sleep-hygiene advice..

Are there other off-label sedatives worth knowing about before quetiapine?

Quetiapine isn't the only off-label option, and it isn't the best-studied one. Low-dose doxepin, several sedating antidepressants beyond trazodone, and gabapentin for sleep are all reached for off-label, each with its own separate evidence base — and none of them carries an antipsychotic's separate side-effect profile into what is, for most people, a self-limited sleep problem.

None of these options are risk-free, and none replaces a conversation about which one, if any, fits a particular person's health history. But comparing quetiapine only to no treatment at all misses the point: the real comparison is to a shelf of other off-label choices, most of which have been studied more directly for sleep than quetiapine has.

When might quetiapine still make clinical sense?

There are situations where it does. Someone already taking quetiapine for schizophrenia or bipolar disorder, whose sleep improves as a secondary effect of treating the underlying condition, is in a meaningfully different position than someone with no psychiatric diagnosis who is offered it as a first attempt at fixing insomnia. The clinical reasoning is specific to the person, not a rule this article can generalize into a checklist.

That distinction — treating an underlying condition versus treating insomnia in isolation — is worth raising directly with the prescribing clinician, alongside a plain question: what would be tried first if sleep were the only problem.

What's a reasonable way to weigh the trade-off?

Start from what's actually being compared. On one side is a medication with essentially no dedicated insomnia trials, no guideline endorsement, and a separate risk profile borrowed from a different condition entirely. On the other side is a therapy with the strongest recommendation a major sleep-medicine guideline gives to anything, and off-label sedatives that, while imperfect, have at least been studied for the specific problem at hand.

That comparison doesn't mean quetiapine is never reasonable — it means the burden of justification sits with quetiapine, not with the alternatives. A useful question to bring into any conversation about it is simple: what, specifically, makes this situation different from the general case where guidelines and evidence point elsewhere first. If there's a clear answer, that's a sign the off-label choice was made deliberately. If there isn't, it's worth asking why quetiapine is the plan rather than a starting point that has actually been tested for sleep.